New product: Daurismo (glasdegib) 25 and 100 mg film-coated tablets

Glasdegib, an inhibitor of the Hedgehog signal transduction pathway, is licensed, in combination with low-dose cytarabine, for treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy.

Source:

electronic Medicines compendium